Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marijn Vis

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Arthritis Research & Therapy|January 18, 2019
Time to minimal disease activity in relation to quality of life, productivity, and radiographic damage 1 year after diagnosis in psoriatic arthritisKim Wervers, Jolanda J Luime, Ilja Tchetverikov, et al.
Rheumatology (Oxford, England)|June 19, 2019
Comparison of disease activity measures in early psoriatic arthritis in usual careKim Wervers, Jolanda J Luime, Ilja Tchetverikov, et al.
RMD Open|June 23, 2026
Frequency of complex-to-manage, difficult-to-manage and treatment-refractory psoriatic arthritis: applying the 2025 GRAPPA and EULAR definitions in a real-world longitudinal PsA cohortGonul Hazal Koc, Marc R Kok, Selinde V J Snoeck Henkemans, et al.
RMD Open|October 18, 2024
Combining patient-reported outcome measures to screen for active disease in rheumatoid arthritis and psoriatic arthritisAgnes E M Looijen, Selinde V J Snoeck Henkemans, Annette H M van der Helm-van Mil, et al.
The Lancet. Rheumatology|November 23, 2025
Intensive biological DMARD-first strategy versus standard step-up care in psoriatic arthritis (STAMP): 1-year results from a multicentre, open-label, randomised controlled trial comparing two treat-to-target strategiesGonul Hazal Koc, Marc R Kok, Fazira R Kasiem, et al.
RMD Open|March 13, 2025
Rheumatoid arthritis and psoriatic arthritis: is the disease impact different? A large matching study at diagnosis and after 1 year of treatmentSelinde V J Snoeck Henkemans, Anne-Fleur van den Biggelaar, Elise van Mulligen, et al.
The Journal of Rheumatology|May 15, 2025
The Effect of Early Attainment of Minimal Disease Activity on Radiographic Outcomes: A Real-World Longitudinal Cohort Study in Psoriatic ArthritisGonul Hazal Koc, Marc R Kok, Selinde V J Snoeck Henkemans, et al.
Annals of the Rheumatic Diseases|May 17, 2025
Disease-modifying antirheumatic drug-free remission in psoriatic arthritis: is it attainable and sustainable? A large longitudinal studySelinde V J Snoeck Henkemans, Marijn Vis, Gonul Hazal Koc, et al.
RMD Open|February 27, 2024
Window of opportunity in psoriatic arthritis: the earlier the better?Selinde V J Snoeck Henkemans, Pascal H P de Jong, Jolanda J Luime, et al.
The Journal of Rheumatology|November 1, 2022
Management of Dactylitis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment RecommendationsPenélope Esther Palominos, Daniel G Fernández-Ávila, Laura C Coates, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Arthritis Research & Therapy|January 18, 2019
Time to minimal disease activity in relation to quality of life, productivity, and radiographic damage 1 year after diagnosis in psoriatic arthritisKim Wervers, Jolanda J Luime, Ilja Tchetverikov, et al.
Rheumatology (Oxford, England)|June 19, 2019
Comparison of disease activity measures in early psoriatic arthritis in usual careKim Wervers, Jolanda J Luime, Ilja Tchetverikov, et al.
RMD Open|June 23, 2026
Frequency of complex-to-manage, difficult-to-manage and treatment-refractory psoriatic arthritis: applying the 2025 GRAPPA and EULAR definitions in a real-world longitudinal PsA cohortGonul Hazal Koc, Marc R Kok, Selinde V J Snoeck Henkemans, et al.
RMD Open|October 18, 2024
Combining patient-reported outcome measures to screen for active disease in rheumatoid arthritis and psoriatic arthritisAgnes E M Looijen, Selinde V J Snoeck Henkemans, Annette H M van der Helm-van Mil, et al.
The Lancet. Rheumatology|November 23, 2025
Intensive biological DMARD-first strategy versus standard step-up care in psoriatic arthritis (STAMP): 1-year results from a multicentre, open-label, randomised controlled trial comparing two treat-to-target strategiesGonul Hazal Koc, Marc R Kok, Fazira R Kasiem, et al.
RMD Open|March 13, 2025
Rheumatoid arthritis and psoriatic arthritis: is the disease impact different? A large matching study at diagnosis and after 1 year of treatmentSelinde V J Snoeck Henkemans, Anne-Fleur van den Biggelaar, Elise van Mulligen, et al.
The Journal of Rheumatology|May 15, 2025
The Effect of Early Attainment of Minimal Disease Activity on Radiographic Outcomes: A Real-World Longitudinal Cohort Study in Psoriatic ArthritisGonul Hazal Koc, Marc R Kok, Selinde V J Snoeck Henkemans, et al.
Annals of the Rheumatic Diseases|May 17, 2025
Disease-modifying antirheumatic drug-free remission in psoriatic arthritis: is it attainable and sustainable? A large longitudinal studySelinde V J Snoeck Henkemans, Marijn Vis, Gonul Hazal Koc, et al.
RMD Open|February 27, 2024
Window of opportunity in psoriatic arthritis: the earlier the better?Selinde V J Snoeck Henkemans, Pascal H P de Jong, Jolanda J Luime, et al.
The Journal of Rheumatology|November 1, 2022
Management of Dactylitis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment RecommendationsPenélope Esther Palominos, Daniel G Fernández-Ávila, Laura C Coates, et al.
Pageof 6